123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 9, 2011, Pages 1648-1658

  Melzer, Henriette Ingrid ^a   Coppenrath, Eva ^a   Schmid, Irene ^a   Albert, Michael H ^a   Von Schweinitz, Dietrich ^a   Tudball, Coral ^b   Bartenstein, Peter ^a   Pfluger, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

123I MIBG scintigraphy; 18F FDG PET; Neuroblastoma; Paediatrics

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; FLUORODEOXYGLUCOSE F 18; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW METASTASIS; BRAIN SCINTISCANNING; CANCER STAGING; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG TUMOR LEVEL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GANGLIONEUROMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; TUMOR VOLUME; COMPARATIVE STUDY; METABOLISM; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

3-IODOBENZYLGUANIDINE; ADOLESCENT; BIOLOGICAL TRANSPORT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; NEUROBLASTOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80955180992     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1843-8     Document Type: Article

References (32)

1. Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. Survival of children with neuroblastoma. time trends and regional differences in Europe, 1978-1992. Eur J Cancer. 2001;37:722-9. (Pubitemid 32304407)
2. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:403-18.
3. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21:181-9. (Pubitemid 30306028)
4. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625-34.
5. Balwierz W, Wieczorek A, Klekawka T, Garus K, Bolek-Marzec K, Perek D, et al. Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group. Przegl Lek. 2010;67:387-92.
6. Perwein T, Lackner H, Sovinz P, Benesch M, Schmidt S, Schwinger W, et al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr Blood Cancer. 2011; doi:10.1002/pbc.23036.
7. Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med. 2003;47:31-40. (Pubitemid 36826759)
8. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123) I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44:1552-8.
9. Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:388-402.
10. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med. 1990;31:129-34. (Pubitemid 20059210)
11. Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000;35:153-5.
12. Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol. 2003;21:1082-6. (Pubitemid 46594137)
13. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743-50.
14. Kushner BH. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med. 2004;45:1172-88. (Pubitemid 47611663)
15. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237-43.
16. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-77. (Pubitemid 23228250)
17. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123) I- metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319-26.
18. Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003;30:B45-50.
19. Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35:1581-8.
20. Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123) I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784-90.
21. Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123I-meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a metaanalysis. J Clin Endocrinol Metab. 2010;95:2596-606.
22. Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol. 2003;181:1115-24. (Pubitemid 37151800)
23. Connolly LP, Drubach LA, Ted Treves S. Applications of nuclear medicine in pediatric oncology. Clin Nucl Med. 2002;27:117-25. (Pubitemid 34075873)
24. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19:3397-405. (Pubitemid 32642193)
25. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679-88. (Pubitemid 28175849)
26. Pfluger T, Schmid I, Coppenrath E, Weiss M. Modern nuclear medicine evaluation of neuroblastoma. Q J Nucl Med Mol Imaging. 2010;54:389-400.
27. McDowell H, Losty P, Barnes N, Kokai G. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2009;52:552.
28. Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009;27:1041-6.
29. Colavolpe C, Guedj E, Cammilleri S, Taieb D, Mundler O, Coze C. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;51:828-31.
30. Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol. 2000;34:237-41. (Pubitemid 30176598)
31. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343-9.
32. Goo HW. Whole-body MRI of neuroblastoma. Eur J Radiol. 2010;75:306-14.